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Abstract
Purpose The Spanish Society of Medical Oncology
(SEOM) has conducted a study on the access to oncologic
drugs across the 17 Spanish Regions with the aim of
identifying potential heterogeneities and making propos-
als for eliminating the barriers identified at the different
levels.
Methods An Expert Panel made up of medical oncologists
designed a survey on certain indications approved for 11
drugs in the approach of breast cancer, melanoma, lung
cancer, prostate cancer and support treatment. This survey
was sent to 144 National Health System (NHS) hospitals.
Results 77 hospitals answered the survey. The information
modules analysed were: scope of the Commission that
establishes binding decisions related to drug access; con-
ditions, stages and periods of drug application, approval
and administration processes; barriers to accessing drugs.
Conclusions The study shows variability in drug access.
The SEOM makes proposals addressed to reducing the
differences identified and homogenizing drug access
conditions.
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Introduction
Cancer represents one of the main health concerns. At the
world level, 14 million of new cases were detected and 8.2
million of deaths were related to cancer in 2012 [1]. The
prevision for the next 20 years is an incidence increase of
around 70 % [2].
In Spain, despite the variability in the quality of epi-
demiological data between the different regions, due to the
heterogeneity of the records used, an estimation of 241,284
new cases were detected in 2014 (145,813 in men and 95,471
in women), the most frequent tumour was colon and rectal
cancer, followed by prostate, lung and breast cancer [3].
Although medical advances in the treatment, prevention
measures and early diagnosis are significantly reducing
mortality and improving life quality of patients with cancer
[4], this disease is in Spain, the main cause of death in men
and the second one in women, following cardiovascular
disease [5].
The use of drugs in the National Health System requires
a series of stages for them to become accessible to patients.
In the European Union (EU), oncologic drugs undergo a
centralised procedure, so that once authorised by the
European Medicines Agency (EMA), authorisation for
commercialization is valid in all the EU countries [6]. In
Spain, subsequently to the approval by the Spanish Agency
of Medicines and Medical Devices (AEMPS), pricing and
reimbursement conditions are established, although in the
case of some drugs the following stage is the elaboration of
the so-called Therapeutic Positioning Report (Informe de
Posicionamiento Terape´utico—IPT) aimed to establish the
basis for the selective funding by consensus of health
professionals and, if appropriate, for pricing and to act as a
reference for any action related to the acquisition and
promotion of a rational use [7]. The price, within the public
health system, is established by the Inter-Ministerial
Commission for Medicines Pricing (Comisio´n Interminis-
terial de Precios de los Medicamentos—CIPM). After-
wards, the Regions cover the pharmaceutical expense, as a
part of their budget. The Regions’ Health Departments,
together with the bodies responsible for the regions’ public
health system management, have prescription information
and monitoring systems, and promote initiatives for
managing the use of drugs.
Patient access to oncological drugs varies widely
between the main developed countries. In 2014, Spain
stood out together with Japan and South Korea for the
limited access to new drugs against cancer commercialised
at the world level; they had only accessed half of the drugs
commercialised during the period 2009–2013 [8].
A study reports that, due to the existence of different
criteria in the decisions on the acquisition and use of
innovative oncologic treatments in the different regions, a
problem of equity arises in the access to therapeutic
innovation for patients from different territories and even
between different hospitals from the same region [9].
Within this context, and based on its commitment with
the best healthcare delivery to cancer patients in equity
conditions, the Spanish Society of Medical Oncology
(SEOM) engaged in this study on the access to oncologic
drugs in the Regions. The aim of the study is to analyse
oncologic drugs traceability in terms of times and mecha-
nisms of approval at different levels. The objectives are to
study possible heterogeneities in patient access to different
approved drug indications throughout the whole country,
establish a solid starting point for solving potential
inequities, and issue proposals for eliminating the barriers
identified at the different levels (national, regional and
hospital).
Materials and methods
An electronic survey was designed aimed to analyse the
standard process undergone by oncologic drugs from
approval at the European level by the EMA to first pre-
scription at hospitals in terms of required stages, their
duration and the involved agents. A Panel of Experts was
established for the elaboration of the survey, made up by
medical oncologists affiliated to SEOM who, additionally,
contributed to the validation of the survey through the
conduction of a pre-test in 5 hospitals from different
regions. The pre-test objectives were to validate the ade-
quacy of the survey for collecting the appropriate infor-
mation to carry out a quality analysis of drug access, and to
analyse its simplicity to be completed by medical oncolo-
gists. It was considered that information would be obtained
in many centres thanks to the collaboration of several
oncologists (for being specialists in the different patholo-
gies included), as well as of pharmacists from the Hospital
Pharmacy Service.
The survey was uploaded to an online platform for facil-
itating its completion. An analysis of the state-of-the-art was
carried out with the resulting data which allowed identifying
areas of improvement and issuing proposals for eliminating
the barriers identified. Another Panel of Experts reviewed
and validated the conclusions of the study.
With the aim of analysing the different access condi-
tions, the survey included the approved indications of 11
drugs for the treatment of breast cancer (pertuzumab,
everolimus, nab-paclitaxel eribulina), melanoma (ipili-
mumab), prostate cancer (abiraterona, cabazitaxel), lung
cancer EGFR ? (gefitinib, erlotinib, afatinib), and support
treatment (denosumab) (Table 1). The reason for selecting
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those drugs and indications was based on both their inno-
vative characteristics and the prevalence of target popula-
tion. The period of time considered for the analysis was
2014.
Open questions were combined with multiple choice
(multiple answer) questions and single answer questions.
Questions were grouped in six modules: centre’s data,
data on drugs for the treatment of breast cancer, data on
drugs for the treatment of melanoma, data on drugs for
support treatment, data on drugs for the treatment of lung
cancer and data on drugs for the treatment of prostate
cancer. The module on the centre collected information on
its reference population, level of complexity, and infor-
mation on the Commission where binding decisions related
to drug access were taken: scope; number of members;
participation of the Medical Oncology Department, the
Hospital Pharmacy Department, the Medical Director and
the Regional Health Service. The objective of this module
was to determine, in the opinion of each centre, which of
the different commissions determined finally the actual use
conditions of each drug and the degree of information on
its composition. The modules about drugs provided
detailed information on the indication included in the
questions, and the IPT if available. In this modules,
information was collected about the date of application of
the drug to the binding Commission for its use in the centre
for that indication; the date of assessment of the drug for
that indication by the binding Commission; the outcome,
that is the approval/refusal of the use of the drug in the
centre; in the case of approval, the conditions of use
approved by the binding Commission; utilization criteria;
the date of first prescription of the drug for that indication
and the number of patients treated with the same drug for
that indication in the year 2014. The objective of this
module of questions was to analyse the differences
between centres regarding the duration of each stage of the
process from approval by EMA to first prescription, the
process’ transparency and the reasons—in the opinion of
oncologists—for explaining use conditions other than the
approved. The detail of the questions is included in
Appendixes 1 and 2.
For the analysis of the time passed between the different
stages required for accessing drugs within their corre-
spondent indications, we considered the approval dates by
Table 1 Approved indications of the 11 analysed drugs in this study
Breast cancer
Pertuzumab Combined with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive locally recurrent
unresectable or metastatic breast cancer, who have not received previous anti-HER2 or chemotherapy treatment for metastatic
disease
Everolimus Treatment of advanced breast cancer, with hormone receptor-positive, HER2/neu-negative, combined with exemestano, in




Indicated in monotherapy for the treatment of metastatic breast cancer in adult patients where first line treatment for metastatic
disease has failed and where standard therapy with anthracycline is not indicated
Eribulina Treatment of patients with locally advanced or metastatic breast cancer with progression after of, at least, two chemotherapy
regimens for advanced disease. Previous therapy must have included anthracycline and taxane in adjuvant or metastatic
framework, unless these treatments were not appropriate for the patients
Melanoma
Ipilimumab Treatment of advanced melanoma (unresectable or metastatic) in adults
Support treatment
Denosumab Prevention of elements related to skeleton (pathologic fracture, bone radiotherapy, spinal cord compression or bone surgery) in
adults with solid tumour bone metastasis
Prostate cancer
Abiraterona Treatment of prostate metastatic cancer resistant to castration in adult men where disease has progressed during or after a
docetaxel-based chemotherapy regimen
Cabazitaxel Combined with prednisona or prednisolona it is indicated for the treatment of patients with metastatic hormone-resistant
prostate cancer, previously treated with a docetaxel-containing therapy
Lung cancer EGFR ?
Gefitinib Treatment of adult patients with locally advanced or metastatic non-microcytic lung cancer with activating mutations of EGFR-
TK
Erlotinib Non-microcytic lung cancer: first line treatment of patients with locally advanced or metastatic non-microcytic lung cancer with
activating mutations of EGFR
Afatinib Indicated as monotherapy in the treatment of adult patients with locally advanced or metastatic non-microcytic lung cancer with
activating mutations of epidermal growth factor receptor (EGFR) not previously treated with a tyrosine-kinase inhibitor of
EGFR
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the EMA and the Spanish Agency of Medicines and Med-
ical Devices (AEMPS), and the date where Pricing and
Reimbursement Conditions (PRC) were established, these
data were requested to pharmaceutical companies com-
mercialising the drugs. The median of months passed from
the date of PRC establishment to the drug’s first prescrip-
tion for the corresponding indication, as well as, the min-
imum and the maximum number of resultant months based
on the answers from the centres participating from each
region, were determined for each drug and indication. The
analysis did not consider first prescription dates precedent
to the date of PRC establishment. Likewise, the global
median of months passed from the date of PRC establish-
ment to the first prescription in the centre was analysed for
each drug.
Access to the survey was available between April and
July 2015, throughout which a monitoring of the comple-
tion process was carried out, as support for solving
potential doubts; e-mail and telephone assistance on
questions interpretation or technical problems was pro-
vided and a follow up of submission deadlines was done.
Quality control was done by providing a summary of the
answers to each centre for its review.
Furthermore, data on the region’s consumption in 2014
were requested to the pharmaceutical companies com-
mercialising the drugs subject of study. Once the required
confidentiality agreements were signed, we had access to
consumption data provided in different variables: units,
sales and % of sales of each region compared to the
national territory of the following drugs: pertuzumab, nab-
paclitaxel, denosumab, ipilimumab, abiraterona, gefitinib,
erlotinib and afatinib; data were standardised to 100,000
inhabitants.
Results
A total of 144 national health system hospitals from the 17
regions were invited to participate in the survey, through
e-mail and telephone contact. The survey was completed by
77 hospitals, which represent 53.5 % of the contacted cen-
tres. From the participant hospitals, 48.1 % presented level 3
of complexity, followed by 37.7 % of level 2 and 14.3 % of
level 1. Concerning the reference population, 27.3 % of the
participating centres covered an area of 300,001–500,000
inhabitants, 16.9 % an area of 250,001–300,000 inhabitants,
14.3 % an area of 500,001–700,000 inhabitants, 11.7 % an
area of more than 700,001 inhabitants, 10.4 % an area of
200,001–250,000 inhabitants, 10.4 % an area of 150,000–
200,000 inhabitants, 5.2 % an area of 100,0001–150,000
inhabitants, 2.6 % an area of\50,000 inhabitants and 1.3 %
an area of 50,001-100,000 inhabitants.
Analysis of the scope of the Commission who establishes
binding decisions related to drug access According to the
answers from the participating centres, the most frequent
scope was the own hospital (65.3 %), followed by the
region (27.8 %). In 5.6 % of the centres Commissions with
more than one scope existed.
Analysis of the procedure of applying for drug use to the
binding Commission 22.1 % of the answers provided by
the centres stated that the use of some of the 11 drugs-
indications subject of analysis had not been requested to
the binding Commission. The causes include: excessive
delay; demotivation due to previous refusals of other
drugs; expensive drugs require an individual report
regardless of their inclusion in the hospital’s guidelines;
high impact drugs do not require application to the
Pharmacotherapy Commission, although they are pre-
scribed according to rigorous practice and based on
therapy recommendation guidelines and IPT; drug access
regulation is done at the regional level and do not require
an application; the drug is not requested because the
patient is referred to the reference centre; the drug is
directly requested to the Hospital Pharmacy Service; low
therapeutic benefit is detected; absence of candidate
patients.
Analysis of drug approval by the binding Commission The
dates of PRC establishment of the 11 drugs analysed in the
study ranged from 2009 (corresponding to the most
ancient) to June 2014 (corresponding to the most recent).
16.1 % of the answers provided by the centres reported
that, to the date of completion of the survey, some of the 11
drugs-indication had not been approved yet for their use in
the centre (10.2 % of answers) or were still pending of
assessment (5.9 % of answers). From this 16.1, 12.3 % of
answers reported the unavailability of procedures for
accessing some of the drugs already approved by the
Spanish Ministry of Health, Social Services and Equity
(MSSSI) and 44.7 % reported the unavailability of mech-
anisms for referring patients to other centres so they could
receive these drugs.
Analysis of the average period from the date of PRC
establishment to drug prescription (Table 2) In relation
with the drugs analysed for approaching breast cancer, the
median of months from PRC establishment to first pre-
scription date, ranged from 6 (pertuzumab) to 23 (nab-
paclitaxel). For pertuzumab variability ranged from 2
(Navarra) to 7 months (Madrid; Arago´n). For nab-pacli-
taxel variability ranged from 17 (Arago´n) to 58 months
(Castilla y Leo´n). For eribulina it ranged from 1 (Cantab-
ria) to 16 months (Comunidad Valenciana). The date of
PRC establishment for everolimus was not available,
therefore, the analysis of this drug was done considering
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the date of approval by the AEMPS, so conclusions are not
comparable to the rest of the drugs.
Concerning the median of months passed from notifi-
cation of PRC by the MSSSI to first prescription of ipili-
mumab, the period ranged from 8 (Andalucı´a) to
27 months (Principado de Asturias). For denosumab,
variability ranged from 3 (Comunidad Valenciana; Cata-
lun˜a) to 24 months (Andalucı´a).
Concerning the drugs analysed for the treatment of
prostate cancer, both showed a median period of
21 months. Individually, in abiraterona (for post-
chemotherapy indication) variability ranged from 5 (An-
dalucı´a) to 31 months (Madrid) while in cabazitaxel,
variability ranged from 2 (Galicia) to 44 months (Castilla
la Mancha).
Concerning the drugs analysed for the treatment of
lung cancer, variability in the median of months ranged
from 9 (afatinib) to 16 months (gefitinib). When analys-
ing each drug separately, a high variability was also
observed among regions concerning the median of
months from PRC establishment to prescription in each
centre. Thus, for gefitinib variability ranged from 5
(Castilla la Mancha) to 51 months (Canarias), for erloti-
nib it ranged from 1 (Cantabria) to 19 months (Madrid)
and for afatinib it ranged from 5 (Madrid) to 12 months
(Cantabria).
Analysis of the stages’ duration from drug approval by
EMA to first prescription (median and ranges) (The anal-
ysis did not consider first prescription dates precedent to
the date of PRC establishment for avoiding considering
drug prescription previous to commercialisation in
Spain, such as compassionate drug use in research).
According to the information provided by the centres on
the date of drugs’ first prescription, the median of
months from approval date by the EMA/AEMPS to first
prescription was 24 months, with 212 answers received,
the minimum period reported in the survey was lower
than 1 month (1 answer) and the maximum 74 months
(1 answer).
Concerning the period of months from approval by
AEMPS to the date of publication of the IPT, if appro-
priate, a median of 24 months was registered.
Transversal analysis of drug approval condition. From the
total of answers provided with relation to drug approval,
54.2 % reported that some of the 11 drugs were approved
with the same conditions established in the Data Sheet or
in the IPT (if available). From the other 45.8, 21.7 %
reported that they accessed to some of the 11 drugs anal-
ysed with different conditions than the ones established in
Data Sheet/IPT, and 16.1 % reported that some of the 11
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Identification of barriers in drug access 37.8 % of answers
reported the existence of barriers or limitations to accessing
some of the drugs subject of study. The most frequent
barriers reported by the centres were the application of
more restrictive criteria than the established in the Data
Sheet and IPT and the existence of a Regional Commission
of Harmonization, due to the delay this could involve in the
approval process. Detailed information on the main barriers
identified is included in Table 3.
Consumption results by drugs and by Regions Significant
differences were observed in the consumption profile of the
same drug in the different Regions, which did not depend
on demographic characteristics and were difficult to
explain only by clinical variability. Detailed information
on the results is included in Appendix 3.
Discussion
SEOM, referent society for Medical Oncology in Spain, from
its commitment with the specialty and the promotion of the
best cancer care delivery, decided to boost the elaboration of
this study on patient access to oncologic drugs. SEOM
considers that the identification of potential inequities and
the proposal of improvements contributing to ensure the
access to drugs in equal conditions throughout the national
territory is a major priority. All this without prejudice of the
measures trending to rationalize prescription and use of
drugs and health products taken by the regions in the course
of their responsibilities, as established in the modification of
Article 88.1 of December 2014 of Law 29/2006 on
guaranties and rational use of drugs and health products.
SEOM denounced before the Ombudsman, in April 2014, the
delays in the introduction of new drugs and territorial
inequities in drug access [10]. The Spanish Society of
Hospital Pharmacy has also shown its concern to this regard
and has declared in favour of promoting a rapid access to
oncologic drugs for patients with clinical benefit, and of
promoting equity in the access to health resources [11].
At the European level, this concern has been reported in
recent studies showing that the access to oncologic drugs in
the European Union is significantly different in the member
states, and there is a need of carrying out initiatives focused
in ensuring equal access to patients in the whole European
Union [12].
The main limitations identified in the study are the
margin of error due to the lack of completion of the
whole survey by the centres invited to participate and
the limited number of answers received for some of the
items, which has not allowed comparisons and conclu-
sions. Nevertheless, drug consumption patterns provided
by pharmaceutical laboratories represent the whole
Spanish population and the centres having answered the
survey represent oncologic care delivery to half of the
Spanish population.
Although the study has focused only in 11 drugs, and the
answers obtained represent slightly more than 50 % of the
centres, obtained data show three major concerns related to
patients’ accessibility to the oncologic drugs analysed. The
detail of the participation per Region is included in
Appendix 4.
The first one is the long time passed between drug
approval by EMA and Pricing and Reimbursement
Fig. 1 Centres responses
distribution at different stages of
the drugs approval and access
process since their request to the
binding Pharmacy and Therapy
Commission (% of total
responses)
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Conditions establishment in Spain, which is a ‘‘sine qua
non’’ condition for prescription.
The second one is variability between Regions and
between different centres from the same Region, con-
cerning the time from Pricing and Reimbursement Condi-
tions establishment to first prescription. Based on the
received answers, drugs showing higher medians of time
from Pricing and Reimbursement Conditions establishment
to first prescription are nab-paclitaxel (23 months), abi-
raterona (21 months), cabazitaxel (21 months) e ipili-
mumab (19 months). Analysis of months passed from
approval by EMA to first prescription shows that period
ranges from a period lower than 1 month to 74 months,
with a median of 24 months.
The third concern identified is variability between
Regions and between centres from the same Region, con-
cerning the scope of the assessment Commissions where
binding decisions related to drug access are taken as well as
the lack of information and homogeneity in the criteria for
modifying prescription conditions within the mentioned
Commissions. 37.8 % of participants identified access
barriers, mainly associated to the high number of assess-
ment commissions and to the need of elaborating a specific
report for each patient despite the previous establishment
of prescription conditions by a commission, which are
often more restrictive than the ones approved by EMA.
This arbitrariness involves that in 45.8 % of the centres
drugs are either approved in conditions which are more
restrictive than the ones in the Data Sheet/IPT or not
approved, which clearly conditions variability in the
access, and makes final prescription conditions heteroge-
neous and more restrictive in general.
Variability in the decision to include new drugs by
Hospital Commissions in Spain has also been subject of other
studies [13]. SEOM considers it is relevant that, despite the
existence of common documents such as the EMA approval
conditions or the IPT, it is at the hospital level where binding
decisions related to drug access are more often taken
(65.3 %), which causes heterogeneity in each centre’s ser-
vices portfolio and a vulnerability situation both for patients
and doctors, as they cannot access drugs in already approved
conditions in our country. Furthermore, we consider it is a
priority to analyse the potential impact of these facts on
patients’ health outcomes depending on the identified access
differences. Therefore, we defend that, in harmony with the
criteria established for drug funding, final use conditions
must arise from a national consensus and be compulsory. It is
important to remind that the National Government has
exclusive authority for determining which drugs are fund-
able as well as the funding conditions. Roya-Decree-law
16/2012, of the 20th of April, on urgent measures for
ensuring sustainability of the National Health System and
improving the quality and safety of services provided,
established that: ‘‘Regions will not be allowed to establish,
unilaterally, specific singular reserves of prescription, pro-
vision and funding of drugs or health products’’.
On the other hand, the survey conclusions are consistent
with the striking differences between Regions identified
Table 3 Main access barriers identified by participant centres
Scope Barrier identified
Barriers related to the existence of regional
Commissions
Drug to be approved by the Regional Harmonization Commission
Drug use is authorised by a Regional Sub-commission.
Drug is pending of assessment by the Regional Pharmacy Commission
Barriers related to budgetary issues High price of the drug and lack of hospital budget
Implantation of debt ceiling systems
Approval of drugs with the same indication and lower price
Barriers related to the centres’ specific procedures
of application/approval and use
Need of a justification report for each patient
Drug not included in the centre’s Pharmacotherapy Guidelines
Use of the drug in exceptional conditions
Compulsory referral of patients to the reference centre
Following to the medical oncologist report, the Hospital Pharmacy Service elaborates
another report and authorisation is requested to Medical Director
Drug assessment in a Special Commission for high economic impact drugs
Delay in the application to the Commission where binding decisions related to drug access
are taken
Delays in the approval process
Drug has been approved in conditions which are more restrictive than the ones in the Data
Sheet and Therapeutic Positioning Report
348 Clin Transl Oncol (2017) 19:341–356
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from the analysis of drug consumption per capita and per
Region according to the data provided by the pharmaceu-
tical industry.
As a result of the study, we have also identified a lack of
transparency and accessibility to the information related to
the different stages and periods undergone by a drug from
the EMA approval to the moment it is available for patients
in the different Regions. European studies show a lack of
accessibility to the information related to drug assessment
procedure and decision-making on Pricing and Reim-
bursement Conditions [14], and alert on the potential
consequences on patients health [15]. SEOM calls for a
higher transparency and accessibility to information on the
status of drugs throughout the assessment process by the
different national, regional or local commissions.
SEOM declares also its concern on the lack of identifi-
cation of a common pattern that explains the variability
identified for the 11 analysed drugs between centres from
the same region and between different regions, and the
implications for patients, considering that the analysis was
done on indications already approved in our country.
Considering that final decision is independently taken at
each hospital and that decision criteria are not clearly
defined, SEOM considers there is a need of developing and
implementing clinical guidelines that support profession-
als’ prescription decision, and contribute to decrease
heterogeneity in the access to oncologic drugs, considering
an appropriate independent management of each patient.
In this situation and with the aim of making drugs and
technologies that provide the best effectiveness and effi-
cacy outcomes equally available for patients in the whole
national health system, SEOM considers there is a need of
implementing initiatives focused in: reducing the identified
differences and homogenizing access conditions, demand-
ing that these conditions are the ones approved by the
AEMPS or in their absence, the ones proposed by IPT;
reducing the existent delay from European drug approval
and prescription to patients; eliminating regional and hos-
pital barriers that make the actual access to the approved
drugs difficult and increasing transparency in the access to
information related to drug accessibility. SEOM also rec-
ommends the promotion of a national cancer register that
includes variables agreed by consensus, allowing future
measurements of health outcomes and analysis of treatment
effectiveness as the best way of contributing to public
health system’s sustainability in real equity conditions.
Conclusions
This study shows the existence of a number of binding
commissions without common criteria that determine drug
use conditions for indications already approved by EMA,
AEMS and with PRC. The study shows, as well, variability
in the composition of these commissions, in the decision-
making and conclusions process.
The present heterogeneity in drug access and the variability
of prescription criteria directly affects patients, as their access
to certain drugs depends on the region and the centre.
Thus, SEOM considers that the approval’s conditions
for each drug should be equal, independently from Region
or hospital. Therefore, equity in drug access is imperative
for patients care and should not be linked to each Region
budget. SEOM also commits to work with health authori-
ties in implementing oncology diseases management
strategies looking for reducing disparities between regions
and hospitals.
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Appendix 1. Descriptive centre’s details
1. Please select your province (REQUIRED)
2. Please select your hospital level
3. Please select the number of inhabitants of your reference population
4. Please indicate the number of Hospital Pharmacists in your centre’s Oncology Area
5. Please select the scope of your centre’s Pharmacy and Therapy Commission where binding decisions 






ჱ Does not exist
Do you know the number of members of the aforementioned Commission? (REQUIRED)
܆ Yes ჱ No
If yes, please indicate: 
a. Number of members of the aforementioned Commission:
(Range 1-20)  Please click here to select a number
b. Number of Medical Oncologists participating in the Commission:
(Range 1-20) ჱ I don’t know
c. Number of Hospital Pharmacists participating in the Commission:
(Range 1-20) ჱ I don’t know ჱ No
d. Does The Medical Director participate in the aforementioned Commission?
܆ Yes
ჱ No 
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Appendix 2. Data on the access to analysed drugs and indications




If yes, when has the application been submitted (month and year)?
Please include month and year
If no, what was the main reason for not application? (Multiple choice answer) 
ჱ Unofficial negative answer
ჱ Excessive delay
ჱ Excessive burocracy
ჱ It does not affect my prescription
ჱ Other reason. Please specify
2. Has the use of this drug been approved at the hospital?
Yes ჱ No ჱ Pending of assessment ჱ
If no, is there any referral procedure available for referring the patient to another centre where he can 
have access to the drug?
Yes ჱ No ჱ
If no, is there any prescription procedure available for accessing the drug?
Yes ჱ No ჱ
3. When has the drug been assessed (month and year)?  
Please include month and year
ჱ I do not know the date
ჱ The drug has not been assessed
4. If the drug has been approved, has it been approved with the same conditions than the ones included in 
the Data Sheet/ Therapeutic Positioning Report? 
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ჱ It has been approved with the SAME conditions than the ones included in the Data Sheet/Therapeutic 
Positioning Report
ჱ It has been approved with MORE restrictive conditions than the ones included in the Data Sheet/Therapeutic 
Positioning Report 
ჱIt has been approved with LESS restrictive conditions than the ones included in the Data Sheet/Therapeutic 
Positioning Report
ჱ The drug has not been approved
5. When was the drug prescribed to the first patient (month and year)? 
Please include month and year
ჱ The information is not available.
ჱ The drug has not been prescribed to any patient although it is available.
6. The use of the drug in the hospital is regulated according to criteria established by… Please select one or 
multiple options (Multiple choice answer)
ჱ Data Sheet/ Therapeutic Positioning Report
ჱ Regional
ჱ Hospital’s Pharmacy and Therapy Commission
ჱ SEOM Assessment Report
ჱ Genesis Assessment Report
ჱ Unavailable information
ჱ Drug is not available at the centre
ჱ Other Please specify
7. How many patients have been treated with this drug in 2014? 
Please include number of patients
8. Do you identify barriers/ limitations for accessing this drug at your centre?
No ჱ Yes ჱ
If yes, please select one or multiple options related to the drug access barriers at your centre (Multiple choice 
answer) 
ჱ Criteria established by the centre are more restrictive than the ones included in the Data Sheet. 
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Appendix 3. Consumption results by drug and Region. Per capita sold units rate or per capita sales
(according to the information provided by laboratories) and region of some of the analysed drugs
standardized to 100,000 inhabitants
ჱ A justification report is required for each patient.
ჱ Debt ceiling systems have been established.
ჱ No medical oncologists participate in the Pharmacy and Therapy Commission.
ჱ Lack of hospital budget
ჱ Burocracy, lack of transparency in information and bad management of delays
ჱ Regional Harmonization Commission
ჱ Another drug with the same indication and lower price has been approved
ჱ Treatment sequence is not allowed for the same indication
ჱ Other use barriers. Please specify
9. Please include other relevant comments.
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Appendix 4. Participant hospitals per Region
Region Number of hospitals requested
to participate in the study
Number of centers that finally
participate in the study
Participation
rate (%)
Andalucı´a 18 10 56
Arago´n 7 3 43
Asturias 2 1 50
Baleares 3 3 100
Canarias 4 2 50
Cantabria 2 1 50
Castilla La Mancha 7 4 57
Castilla y Leo´n 8 3 38
Catalun˜a 25 13 52
Ceuta 1 0 0
C de Madrid 23 13 57
C. Valenciana 20 12 60
Extremadura 4 1 25
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continued
Region Number of hospitals requested
to participate in the study
Number of centers that finally
participate in the study
Participation
rate (%)
Galicia 9 5 56
La Rioja 1 1 100
Navarra 1 1 100
Paı´s Vasco 6 2 33
Regio´n de Murcia 3 2 67
Total 144 77 53.5
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